Data/hora: 10/06/2024 05:39:22

Provedor de dados: 	5	
País: 	France	
Título: 	Antiproliferative Activity of Violaxanthin Isolated from Bioguided Fractionation of Dunaliella tertiolecta Extracts	
Autores: 	Pasquet, Virginie; Morisset, Perrine; Ihammouine, Said; Chepied, Amandine; Aumailley, Lucie; Berard, Jean-baptiste; Serive, Benoit; Kaas, Raymond; Lanneluc, Isabelle; Thiery, Valerie; Lafferriere, Mathieu; Piot, Jean-marie; Patrice, Thierry; Cadoret, Jean-paul; Picot, Laurent.	
Data: 	2011-05	
Ano: 	2011	
Palavras-chave: 	Pigments; Microalgae; Dunaliella; Violaxanthin; Carotenoid; Cancer; Apoptosis.	
Resumo: 	Dunaliella tertiolecta (DT) was chemically investigated to isolate molecules inhibiting cancer cell proliferation and inducing apoptosis in vitro. The potency to inhibit cell growth was used for the bio-guided fractionation and isolation of active compounds using chromatographic techniques. The DT dichloromethane extract exhibited a strong anti-proliferative activity on MCF-7 and LNCaP cells, and was further fractionated and sub-fractionated by RP-HPLC. High resolution mass spectrometry and spectrophotometric analysis unequivocally identified violaxanthin as the most antiproliferative molecule present in DT DCM extract. Violaxanthin purified from DT induced MCF-7 dose- dependent growth inhibition in continuous and discontinuous treatments, at concentrations as low as 0.1 mu g.mL(-1) (0.17 mu M). Phosphatidylserine exposure, typical of early apoptosis, was observed after 48 h treatment at 8 mu g.mL(-1) (13.3 mu M) but no DNA fragmentation, characteristic of late apoptosis steps, could be detected even after 72 h treatment at 40 mu g.mL(-1) (66.7 mu M). Taken together, our results demonstrate the strong antiproliferative activity of violaxanthin on one human mammary cancer cell line, and suggest that studying the pharmacology of violaxanthin and pharmacomodulated derivatives on cancer cells may allow potent antiproliferative drugs to be obtained.	
Tipo: 	Text	
Idioma: 	Inglês	
Identificador: 	http://archimer.ifremer.fr/doc/00040/15142/12575.pdf

DOI:10.3390/md9050819	
Editor: 	Mdpi Ag	
Relação: 	http://archimer.ifremer.fr/doc/00040/15142/	
Formato: 	application/pdf	
Fonte: 	Marine Drugs (1660-3397) (Mdpi Ag), 2011-05 , Vol. 9 , N. 5 , P. 819-831	
Fonte: 	2011 MDPI Publishing